Relentlessly fighting a smarter war against GI cancer by partnering with patients based on their unique needs, the Ruesch Center is committed to providing you with the highest standard of care and individualized cures.
Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute (TGen), an affiliate of the City of Hope, is one of five leading researchers who will receive a Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers.
The combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma (HCC).
Bell-ringing ceremonies to mark the end of a cancer treatment are now widespread at cancer clinics around the US. For metastatic cancer patients, who cannot "beat" cancer, the sound of the bell can trigger anger, resentment, resignation, or depression.
When Meeghan DeCagna was diagnosed with a rare GI cancer, called a GIST, and targeted therapy was unsuccessful, her only option was surgery to remove a six pound tumor. She found Director of Surgical Oncology at MedStar Georgetown, Waddah Al-Refaie, MD to lead her complicated operation.
Keith Unger, MD, is a Board-certified radiation oncologist, who specializes in the use of proton therapy and other radiation treatments for gastrointestinal cancers at MedStar Georgetown University Hospital.
Sign Up to receive all Ruesch updates directly in your Inbox
We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.